Skip to search formSkip to main contentSkip to account menu

pexelizumab

Known as: h5G1.1-SC, h5G1.1-scFv 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Antibodies, Monoclonal, HumanizedSingle-Chain Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study).
Review
2007
Review
2007
Innate immunity-mediated allograft rejection and strategies to prevent it.
Review
2007
Review
2007
Inhibitors of the complement system currently in development for cardiovascular disease
Controlled activation of the complement system is critical to the host-defense response of the immune system. Activated… 
2007
2007
Pexelizumab does not "complement" percutaneous coronary intervention in patients with ST-elevation myocardial infarction.
TIMELY RESTORATION OF CORONARY ARTERY BLOOD flow using thrombolytic therapy, percutaneous coronary intervention (PCI), or… 
2006
2006
Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction.
Review
2006
Review
2006
[Clinical aspects of the complement system].
The complement system consists of more than 30 proteins and has 3 types of activation pathways: classical, lectin and alternative… 
Highly Cited
2005
Highly Cited
2005
Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial…
Review
2005
Review
2005
Pexelizumab: a novel therapy for myocardial ischemia-reperfusion.
Despite significant advances in the study of myocardial reperfusion, patients with epicardial coronary reperfusion still have… 
2005
2005
Pexelizumab – a C5 complement inhibitor for use in both acute myocardial infarction and cardiac surgery with cardiopulmonary bypass
Myocardial injury and dysfunction in acute infarction and during cardiac surgery with cardiopulmonary bypass (CPB) are associated… 
Highly Cited
2004
Highly Cited
2004
Preliminary Report of the Effects of Complement Suppression With Pexelizumab on Neurocognitive Decline After Coronary Artery Bypass Graft Surgery
Background and Purpose— Pharmacological modulation of complement activation recently has been postulated as a therapeutic target… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)